Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Editor

Personal info

View

About

Terms

Javascript disabled

Please enable Javascript support in your browser to use this application.

Instructions on how to enable JavaScript on different browsers can be found here: http://www.google.com/support/bin/answer.py?answer=23852.

[edit this page]

Chemical Compound Review:

Simendan 2-[[4-(4-methyl-6-oxo-4,5- dihydro-1H...

Synonyms: dextrosimendan, Simendan [INN], CHEMBL313136, OR-1259, CHEBI:240651, ...

Lilleberg, J. et al., Levijoki, J. et al., Lilleberg, J.M. et al., Li, F. et al.

Levijoki, Pollesello, Kaheinen, Haikala, Li, Zhang, Lu, Wang, Xiong,

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Simendan

OBJECTIVE: To assess pharmacokinetics and correlation of pharmacokinetics and pharmacodynamics of simendan, a new calcium-sensitizing compound aimed at the treatment of congestive heart failure, in healthy volunteers [1].
Improved survival with simendan after experimental myocardial infarction in rats [2].

High impact information on Simendan

Pharmacokinetics and pharmacodynamics of simendan, a novel calcium sensitizer, in healthy volunteers [1].
One subject after 5 mg simendan and one subject after 10 mg simendan had transient vasovagal reactions consisting of decreases in heart rate and blood pressure [1].
These results revealed that simendan has hemodynamic effects that can be explained by positive inotropy as well as vasodilatation, in agreement with preclinical findings [3].

Chemical compound and disease context of Simendan

These findings suggest that, like enalapril, simendan improved survival in rats with healed myocardial infarction [2].

Analytical, diagnostic and therapeutic context of Simendan

The chiral separation of simendan enantiomers using capillary electrophoresis was studied with beta-cyclodextrin (beta-CD) as chiral selector [4].

References

Pharmacokinetics and pharmacodynamics of simendan, a novel calcium sensitizer, in healthy volunteers. Lilleberg, J., Antila, S., Karlsson, M., Nieminen, M.S., Pentkäinen, P.J. Clin. Pharmacol. Ther. (1994) [Pubmed]
Improved survival with simendan after experimental myocardial infarction in rats. Levijoki, J., Pollesello, P., Kaheinen, P., Haikala, H. Eur. J. Pharmacol. (2001) [Pubmed]
Hemodynamic effects of the novel cardiotonic drug simendan: echocardiographic assessment in healthy volunteers. Lilleberg, J.M., Sundberg, S., Leikola-Pelho, T., Nieminen, M.S. Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy. (1994) [Pubmed]
Enatiomeric analysis of simendan by CE with beta-CD as chiral selector compared with CMPA-HPLC. Li, F., Zhang, D., Lu, X., Wang, Y., Xiong, Z. Biomed. Chromatogr. (2004) [Pubmed]

Contributions to this collaborative article are from individual authors of WikiGenes or mined by the WikiGenes Data Mining Engine from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenes Open Access Licence Privacy Policy Terms of Use apsburg